Topic:

M&A

Latest Headlines

Latest Headlines

What's Mylan worth? For big exec bonuses, $73 per share. For Teva, lots more

Mylan may be demanding more than $100 per share from suitor Teva if it wants to talk takeover. But for itself--and its executives--its expectations aren't nearly that high.

One 'cultural difference' between Teva and Mylan? Coury's $22.5M pay wouldn't fly at Teva

Since before Teva even made its now-rejected $40 billion offer to buy Mylan, its target's exec chairman, Robert Coury, has been pretty down on the idea, citing a potential culture clash between the two companies. While Teva CEO Erez Vigodman has said he thinks they'd get along just fine, the rival drugmakers do have a few big differences between them--including their approach to executive compensation.

Gilead's 'open to suggestion' on its next big M&A splash

On pace to reap $29 billion in revenue this year thanks to its surging hepatitis C franchise, Gilead Sciences has the cash to pull off a big deal or two, and management is eyeing a slew of late-stage opportunities.

Teva CEO 'takes the high road' to rebut Mylan chairman's attack

Hold it right there, Mylan, Teva said in a Wednesday letter to that company's executive chairman. A couple days after receiving a scathing rejection to its $40 billion buyout bid, the Israeli drugmaker has a few things it wants to set straight.

WuXi's CEO moves to take the CRO private

WuXi PharmaTech's CEO has teamed up with a major investor in an attempt to take the CRO private, pitching a buyout that would give the Chinese company's shareholders a 16.2% premium.

UPDATED: Third time's no charm for Mylan as Perrigo shoots down latest bid

With Mylan's second bid for Perrigo, it actually hit below the first bid the Irish drugmaker rejected, Perrigo contended. But now, Mylan is back with a third offer to set things straight.

Rare-disease specialist Sobi entertains suitors for potential $3.5B-plus deal

Orphan meds have been like catnip for drugmakers for several years, driving many an M&A deal. Now, Swedish Orphan Biovitrum might be next in line, at a price of more than $3.5 billion.

Undeterred by Perrigo rejection, Mylan tells Teva to step off

On Friday, Mylan all but rejected Teva's takeover bid with its own sweetened bid for Ireland's Perrigo. But now, it's made the snub official, delivering a resounding "no" to its generics rival.

Celgene bags a build-to-buy biotech in $485M cancer deal

A few years after teaming up with Versant Ventures to get Stanford spinout Quanticel Pharmaceuticals off the ground, Celgene is buying the cancer-focused biotech for up to $485 million.

Biogen partner Sobi and its Boston-based CEO field a takeover bid

Sweden's Sobi, a close partner of Biogen, is in the crosshairs of a buyout bid. But the biotech isn't saying yet just who's doing the bidding.